Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 17,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 17,5 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 17,5 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 30 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 30 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 30 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 10 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 12,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 12,5 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 12,5 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 15 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 15 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg

Metojectpen (Metoject) Stungulyf, lausn í áfylltum lyfjapenna 22,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 22,5 mg

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 22,5 mg

Imjudo Evrópusambandið - íslenska - EMA (European Medicines Agency)

imjudo

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Æxlishemjandi lyf - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Tremelimumab AstraZeneca Evrópusambandið - íslenska - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Myfortic Magasýruþolin tafla 180 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

myfortic magasýruþolin tafla 180 mg

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 180 mg

Myfortic Magasýruþolin tafla 360 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

myfortic magasýruþolin tafla 360 mg

novartis healthcare a/s - mycophenolatum natríum - magasýruþolin tafla - 360 mg